Compare MSN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSN | GTBP |
|---|---|---|
| Founded | 1948 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.8M |
| IPO Year | 1995 | 2016 |
| Metric | MSN | GTBP |
|---|---|---|
| Price | $0.38 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 112.6K | ★ 1.5M |
| Earning Date | 02-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,829,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $0.26 |
| 52 Week High | $0.85 | $3.73 |
| Indicator | MSN | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 60.81 |
| Support Level | $0.36 | $0.40 |
| Resistance Level | $0.41 | $0.59 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 23.80 | 94.36 |
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.